Puma Biotech (PBYI) Defended at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Puma Biotechnology (PBYI) Abstract Data Helps Explain Need to Change Trial - RBC
November 14, 2016 12:30 PM ESTRBC Capital analyst Simos Simeonidis weighed in on Sector Perform-rated Puma Biotechnology (NYSE: PBYI) amid SABCS loperamide prophylaxis data show a higher than expected Grade 3 diarrhea rate. He said the data helps eplains the need to try new regimen.
commented, ". In an abstract released this morning, Puma disclosed data from the Phase II CONTROL trial in the extended adjuvant setting showing that treatment with loperamide helps lower the ~40%... More
Stifel Says Puma Biotechnology (PBYI) Abstract Somewhat Concerning, But Sell-Off Appears to be an Over Reaction
November 14, 2016 12:17 PM ESTStifel analyst Thomas Shrader weighed in on Puma Biotechnology (NYSE: PBYI) after the company's San Antonio abstract is out and the diarrhea rate for the complete CONTROL trial looks about twice what was indicated in the early look (27% (n=133) vs. 16% (n=50)).
Shrader commented, "This is somewhat disturbing as this abstract... More
Puma Biotech (PBYI) options active on sharp sell off
November 14, 2016 11:20 AM ESTPuma Biotech (NYSE: PBYI) November 35 and 41 calls are active on total call volume of 1,900 contracts (900 puts). November call option implied volatility is a 233, December is at 124; compared to its 52-week range of 67 to 114.
... MoreCascadian Therapeutics (CASC) Sees Upside on Puma Biotech (PBYI) Stumble
November 14, 2016 10:57 AM ESTCascadian Therapeutics (NASDAQ: CASC) gaining related to the plunge in Puma Biotech (NYSE: PBYI).
... MorePuma Biotech (PBYI) Halted on Circuit Breaker
November 14, 2016 10:48 AM ESTPuma Biotech (NYSE: PBYI) Halted on Circuit Breaker
... MoreUPDATE: Puma Biotech (PBYI) Sees Heavy Selling Pressure; SABCS Abstracts Released
November 14, 2016 10:40 AM EST(Updated - November 14, 2016 10:55 AM EST)
Puma Biotech (NYSE: PBYI) is under heavy pressure. Shares down 17.7%
UPDATE: Downdside could be coming as SABCS abstracts were released. Link
There is also talk amongst traders about a PR Friday discussing a shareholder investigation. Shares last traded down 35% before being halted on a circuit breaker.
... More
